Document:

Unanimous Written Consent of the Board of Managers

 Exhibit 10.4(d) 
  
 UNANIMOUS WRITTEN CONSENT 
 OF THE BOARD OF DIRECTORS OF 
 RELIANT PHARMACEUTICALS, INC. 
  
 The undersigned, being all of the directors of Reliant Pharmaceuticals, Inc.,
a Delaware corporation (the “Corporation”), in lieu of a meeting of the Board of Directors of the Corporation (the “Board”) and pursuant to the authority of Section 141(f) of the Delaware General Corporation Law and
Article III, Section 8 of the By-Laws of the Corporation, hereby consent to, authorize and adopt the following resolutions with the same force and effect as if the undersigned were personally present at a meeting of the Board and had voted for the
same. Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Plan of Conversion (as defined below). 
  
 Adoption of Equity Incentive Plan and Assumption of Certain Obligations Related to Stock Options and Warrants 
  
 WHEREAS, the Board of Managers of the Corporation’s
predecessor, Reliant Pharmaceuticals, LLC, approved and ratified, and the Corporation has adopted, a Plan of Conversion, dated as of March     , 2004, a copy of which is attached as Exhibit A (the “Plan of
Conversion”), pursuant to which, among other things, (i) Reliant Pharmaceuticals, LLC converted into the Corporation and (ii) the Reliant Pharmaceuticals, LLC Equity Incentive Plan (the “LLC Equity Plan”) automatically
terminated to the extent necessary such that no further options remain eligible for grant thereunder, although such Plan continues to govern options already issued thereunder; 
  
 WHEREAS, the Plan of Conversion provides that the Corporation shall adopt, and the Board has determined that
it is in the best interests of the Corporation to adopt, the Reliant Pharmaceuticals, Inc. 2004 Equity Incentive Plan substantially in the form attached as Exhibit B (the “2004 Equity Incentive Plan”); 
  
 WHEREAS, the Plan of Conversion provides that the
Corporation shall reserve, and the Board has determined that it is in the best interests of the Corporation to reserve, an aggregate of 1,343,600 shares of Common Stock for issuance under the 2004 Equity Incentive Plan plus any shares subject to
options granted under the LLC Equity Plan which are forfeited or unexercised at the expiration of their term (by cancellation or otherwise); and 
  
 WHEREAS, the Plan of Conversion provides that each option to purchase Common Units (the “Options”) outstanding
immediately prior to the effective time of the corporation conversion (the “Effective Time”) under the LLC Equity Plan, whether or 

 not exercisable, continues to be outstanding according to the terms and conditions as set forth in the
LLC Equity Plan and any option agreements thereunder in effect immediately prior to the Effective Time, except that (i) each such Option is automatically exercisable (or will become exercisable in accordance with its terms) for that number of shares
of Common Stock equal the number of Common Units that were issuable upon exercise of such Option, and (ii) the LLC Equity Plan shall be amended to the extent necessary to reflect the Conversion from a limited liability company to a corporation and
that such Options will be exercisable for shares of Common Stock and not Common Units. 
  
 NOW, THEREFORE, BE IT RESOLVED, that subject to approval by the stockholders of the Corporation, the 2004 Equity Incentive Plan be, and it
is hereby, adopted, authorized and approved in all respects; 
  
 FURTHER RESOLVED, that the Board hereby approves the submission of the 2004 Equity Incentive Plan to the stockholders of the Corporation for their approval and recommends such approval; 
  
 FURTHER RESOLVED, that an aggregate of 1,343,600 shares of
Common Stock are hereby reserved for issuance under the 2004 Equity Incentive Plan in accordance with the terms of the 2004 Equity Incentive Plan, plus any shares subject to options granted under the LLC Equity Plan or the 2004 Equity Incentive Plan
which are forfeited or unexercised at the expiration of their term (by cancellation or otherwise); 
  
 FURTHER RESOLVED, that the Board hereby authorizes, empowers and directs the proper officers of the Corporation to take all actions
necessary to cause the Corporation to (i) assume the obligations of Reliant Pharmaceuticals, LLC with respect to all Options issued and outstanding under the LLC Equity Plan and (ii) settle, as and when appropriate, the Options issued and
outstanding under the LLC Equity Plan with options to purchase Common Stock, which options shall be subject to the terms of the LLC Equity Plan and the option agreements related thereto; provided, however, that the Corporation does not
assume any Options issued under the LLC Equity Plan that are not outstanding at the Effective Time; 
  
 FURTHER RESOLVED that any proper officer may order the transfer agent of the Corporation (which may be the Corporation) to set aside and
reserve that number of shares (the “Underlying Shares”) of the Corporation’s Common Stock, as can be issued upon the exercise of all of the options granted under the 2004 Equity Incentive Plan, options granted under the LLC
Equity Plan and warrants issued by the Corporation (or its predecessors), from the authorized but unissued shares of Common Stock; and 
  
 FURTHER RESOLVED, that upon issuance and delivery of the Underlying Shares against payment of the exercise price therefor in accordance
with the terms of the 2004 Equity Incentive Plan, the LLC Equity Plan or warrants issued by the Corporation (or its predecessors), as applicable, and the option agreements related thereto, the Underlying Shares shall be validly issued, fully paid
and nonassessable. 

 General Resolutions: 
  
 FURTHER RESOLVED, that the proper officers of the Corporation be, and each of them hereby is, authorized,
directed and empowered, in the name and on behalf of the Corporation to negotiate, execute, acknowledge and deliver any and all documents and instruments and to take any and all such actions including making changes to such documents or instruments,
as he may deem necessary or desirable in order to carry out the intent and purposes of the foregoing resolutions, the execution and delivery of such documents or instruments or the taking of such action to be conclusive evidence that such execution
and delivery or the taking of such action was authorized by these resolutions; 
  
 FURTHER RESOLVED, that all actions heretofore taken and expenses incurred by any proper officer heretofore in furtherance of any of the
actions authorized or ratified by the foregoing resolutions, to the extent consistent with such resolutions, hereby are expressly ratified, confirmed, adopted and approved in all respects; 

 FURTHER RESOLVED, that the “proper officers” of the Corporation for the
purposes of these resolutions shall be the Chairman of the Board, the Vice Chairman of the Board, the Chief Executive Officer, the President, any Vice President (regardless of designation), the Secretary and the Treasurer of the Corporation; and

  
 FURTHER RESOLVED, that this written consent
may be executed in one or more counterparts, any of which may be executed and transmitted by facsimile, each of which will be deemed to be an original of this written consent and all of which, when taken together, will be deemed to constitute one
and the same instrument. 
  
 [Signature Page Follows]

 Dated: April 1, 2004 
  

	
	 /s/ Jack L. Bowman

	 Jack L. Bowman

	
	 /s/ Gerald L. Cohn

	 Gerald L. Cohn

	
	 /s/ Fred B. Craves

	 Fred B. Craves

	
	 /s/ Mark S. Hoplamazian

	 Mark S. Hoplamazian

	
	 /s/ Joseph Krivulka

	 Joseph Krivulka

	
	 /s/ Ken Langone

	 Ken Langone

	
	 /s/ Ernest Mario

	 Ernest Mario

	
	 /s/ David V. Milligan

	 David V. Milligan

	
	 /s/ Richard F. Pops

	 Richard F. Pops

	
	 /s/ Thomas J. Pritzker

	 Thomas J. Pritzker

	
	 BEING ALL OF THE MEMBERS
 OF THE BOARD OF
DIRECTORS
 OF THE CORPORATIONForm of Option Agreement under the Reliant Pharmaceuticals Equity Incentive Plan

  
 Exhibit 10.4(e) 
  
 RELIANT PHARMACEUTICALS, LLC 
  
 EQUITY INCENTIVE PLAN 
  
 OPTION AGREEMENT 
  
 Unless otherwise defined herein, capitalized terms shall have the same
meanings as set forth in the Reliant Pharmaceuticals, LLC Equity Incentive Plan (the “Plan”). 
  

	I.	NOTICE OF OPTION GRANT 

  
 [Name] 
  
 You (“Participant”) have been granted an option to purchase Class One Common Units (the “Units”) in the Company, subject
to the terms and conditions of the Plan and this Option Agreement. The terms of your grant are set forth below: 
  

			
	 Date of Grant:
	  	 
		
	 Vesting Commencement Date:
	  	 
		
	 Exercise Price per Unit:
	  	$            
		
	 Units Granted:
	  	 
		
	 Total Exercise Price:
	  	$            
		
	 Expiration Date:
	  	 

  
 Exercise and
Vesting Schedule: 
  
 This Option is exercisable immediately,
in whole, conditioned upon Participant entering into the Exercise Notice and Restricted Unit Agreement (the “Restricted Unit Agreement”) in the form set forth on Exhibit A. This Option shall vest and/or the Units purchased
upon exercise of this Option shall be released from Repurchase, as set forth in the Restricted Unit Agreement according to the following schedule: 
  
 Twenty-five percent (25%) of the Units subject to the Option (rounded down to the next whole number of Units) shall vest on each anniversary of the
Vesting Commencement Date, so that all of the Units shall be vested on the fourth anniversary of the Vesting Commencement Date. 
  
 Termination Period: 
  
 This Option may be exercised for thirty (30) days after Participant ceases to be a Service Provider, or such longer period as may be applicable upon the
death or Disability as provided 

  

 
herein, (or, if not provided herein, then as provided in the Plan), but in no event later than the Term/Expiration Date as provided above. 
  

	II.	AGREEMENT 

  
 1. Grant of Option. The Company hereby grants to the Participant an Option to purchase the number of Units set forth in the Notice of Grant, at the
exercise price set forth in the Notice of Grant (the “Exercise Price”). Notwithstanding anything to the contrary anywhere else in this Option Agreement, this grant of an Option is subject to the terms, definitions and provisions of
the Plan and the LLC Agreement, which are incorporated herein by reference. 
  
 2. Exercise of Option. This Option is exercisable as follows: 
  
 (a) Right to Exercise. 
  
 (i) This Option is exercisable in full upon the date it is granted. 
  
 (ii) This Option may be not be exercised for a partial Unit. 
  
 (iii) In no event may this Option be exercised after the
Expiration Date as set forth in the Notice of Grant. 
  
 (b) Method of Exercise. This Option shall be exercisable by execution of the Restricted Unit Agreement, stating the number of Units for which the Option is being exercised, and such other representations and agreements with respect
to such Units as may be required by the Company pursuant to the provisions of the Plan. The Restricted Unit Agreement must be signed by the Participant and, shall be delivered in person or by certified mail to the Secretary of the Company. The
Restricted Unit Agreement must be accompanied by payment of the Exercise Price, including payment of any applicable withholding tax. This Option shall be deemed to be exercised upon receipt by the Company of the executed Restricted Unit Agreement
accompanied by the Exercise Price and payment of any applicable withholding tax. 
  
 (c) Compliance with Applicable Law. No Units shall be acquired pursuant to the exercise of an Option unless such acquisition and
exercise comply with all relevant Applicable Law. Assuming such compliance, for income tax purposes the Units shall be considered transferred to the Participant on the date on which the Option is exercised with respect to such Units. 
  
 3. Participant’s Representations. At the time this Option is
exercised, Participant shall concurrently with the exercise of all or any portion of this Option, deliver to the Company his or her Investment Representation Statement in the form attached hereto as Exhibit B. 
  
 4. Vesting. Participant shall vest in the Units issuable upon exercise
of this Option as set forth in the Notice of Grant. For purposes of this Option Agreement, the Unit subject to this Option shall vest based on Participant’s continued status as a Service Provider. The vested portion of the Unit shall not be
subject to Repurchase (as set forth in the Restricted Unit Agreement) but shall be subject to the Company’s Right of First Refusal and Call Right as set forth in the Restricted Unit Agreement. 
  

 2 

 5. Method of Payment. Payment of the Exercise Price shall be by any of the following, or a
combination thereof, at the election of the Participant: 
  
 (a) cash; 
  
 (b)
check; or 
  
 (c) with the consent of the
Committee, property of any kind (including the surrender of underlying Units) which constitutes good and valuable consideration. 
  
 6. Term of Option. To the extent that this Option is not vested at the date on which the Participant ceases to be a Service Provider, or if the
Participant does not exercise this Option within the time specified herein, the Option shall terminate. This Option shall terminate on the date Participant ceases to be a Service Provider for Cause. Except as provided in this Section 9, this Option
may be exercised only within the term set out in the Notice of Grant. 
  
 (a) Termination of Relationship. If Participant ceases to be a Service Provider (other than for Cause or by reason of the Participant’s death or Disability), Participant may exercise the vested portion of
this Option during the Termination Period set out in the Notice of Grant. 
  
 (b) Death or Disability of Participant. If Participant ceases to be a Service Provider as a result of death or Disability, the vested portion of the Option as of the date on which such Participant ceased to be
a Service Provider, shall be exercisable at any time within twelve (12) months from such date, but in no event later than the Expiration Date as set forth in the Notice of Grant. 
  
 7. Restrictions on Exercise. If the purchase of the Unit upon such exercise or if the method of payment for such
Units would constitute a violation of any Applicable Laws, then the Option may not be exercised. The Company may require Participant to make any representation and warranty to the Company as may be required by any Applicable Law or regulation before
allowing the Option to be exercised. 
  
 8. Non-Transferability
of Option. This Option may not be transferred in any manner except by will or by the laws of descent or distribution. It may be exercised during the lifetime of Participant only by Participant. Notwithstanding the foregoing the Option may be
transferred to the Participant’s Immediate Family; provided, however, that any such transfer is without payment of any consideration whatsoever, that no such transfer shall be valid unless first approved by the Committee, acting in its sole
discretion, and that any Option so transferred shall remain subject to the terms and conditions of this Option agreement. The terms of this Option shall be binding upon the executors, heirs, successors and assigns of the Participant. 
  
 9. Restrictions on Units. Participant hereby agrees that the Units
purchased upon the exercise of the Option shall be subject to the terms and conditions of the LLC Agreement, and such other terms and conditions as the Committee may determine in its sole discretion, including, without limitation, restrictions on
the transferability of Units, the right of the Company to repurchase Units, and a right of first refusal in favor of the Company with respect to permitted transfers of Units. Such terms and conditions may, in the Committee’s sole discretion, be

  

 3 

 
contained in the Restricted Unit Agreement or in such other agreement as the Committee shall determine and which the Participant hereby agrees to enter into
at the request of the Company upon exercise of the Option. 
  
 10.
Lock-Up Period. Participant hereby agrees that if so requested by the Company (or any successor thereto) or any representative of the underwriters (the “Managing Underwriter”) in connection with any registration of the
offering of any securities of the Company under the Securities Act of 1933, as Amended (the “Securities Act”), Participant shall not sell or otherwise transfer any Units (or any securities of the Company in which such Units may be
converted) or other securities of the Company during the 180-day period (or such longer period as may be requested in writing by the Managing Underwriter and agreed to in writing by the Company) (the “Market Standoff Period”)
following the effective date of a registration statement of the Company filed under the Securities Act; provided, however, that such restriction shall apply only to the first registration statement of the Company to become effective under the
Securities Act that includes securities to be sold on behalf of the Company to the public in an underwritten public offering under the Securities Act. The Company may impose stop-transfer instructions with respect to securities subject to the
foregoing restrictions until the end of such Market Standoff Period. 
  
 [SIGNATURE PAGE FOLLOWS] 
  

 4 

 This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and
all of which shall constitute one document. 
  

			
	RELIANT PHARMACEUTICALS, LLC
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

  
 PARTICIPANT
ACKNOWLEDGES AND AGREES THAT THE OPTION HEREIN GRANTED CONTINUES TO BE EXERCISABLE ONLY FOR PERIODS DETERMINED WITH REFERENCE TO THE PERIOD OF CONTINUED CONSULTANCY OR EMPLOYMENT AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING
GRANTED THIS OPTION OR ACQUIRING UNITS HEREUNDER). PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS AGREEMENT, NOR IN THE COMPANY’S EQUITY INCENTIVE PLAN WHICH IS INCORPORATED HEREIN BY REFERENCE, SHALL CONFER UPON PARTICIPANT
ANY RIGHT WITH RESPECT TO CONTINUATION OF EMPLOYMENT OR CONSULTANCY BY THE COMPANY, NOR SHALL IT INTERFERE IN ANY WAY WITH PARTICIPANT’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE PARTICIPANT’S EMPLOYMENT OR CONSULTANCY AT ANY TIME,
WITH OR WITHOUT CAUSE OR NOTICE. 
  
 Participant acknowledges
receipt of a copy of the Plan and the LLC Agreement and represents that he is familiar with the terms and provisions thereof. Participant hereby accepts this Option subject to all of the terms and provisions thereof. Participant has reviewed the
Plan, the LLC Agreement and this Option in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Option and fully understands all provisions of the Option. Participant hereby agrees to accept as binding,
conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan or this Option. Participant further agrees to notify the Company upon any change in the residence address indicated below. 

 

					
	 Dated:
                    
	 	 	 	  
			
	 	 	 	 	 Residence Address:

			
	 	 	 	 	 
			
	 	 	 	 	 

  

 5 

  
 EXHIBIT A

  
 RELIANT PHARMACEUTICALS, LLC 
  
 EQUITY INCENTIVE PLAN 
  
 EXERCISE NOTICE AND RESTRICTED UNIT AGREEMENT 
  
 Reliant Pharmaceuticals, LLC 
 110 Allen Road 
 Liberty Corner, New Jersey 07938 
  
 Attention:     Secretary 
  
 1. Exercise of Option. Effective as of today,
                    ,         , the undersigned (“Participant”) hereby elects
to exercise Participant’s option to purchase          Class One Common Units (the “Units”) in Reliant Pharmaceuticals, LLC (the “Company”) under and pursuant to
the Reliant Pharmaceuticals, LLC Equity Incentive Plan (the “Plan”) and the Option Agreement dated                     ,
        , (the “Option Agreement”),              portion of the Units have not become vested under the vesting
schedule set forth in the Option Agreement (“Unvested Units”). Upon termination of Purchaser’s status as a Service Provider, the Unvested Units shall be subject to Repurchase as set forth in Section 6 below. The vested portion
of the Units (“Vested Units”) shall not be subject to Repurchase. 
  
 2. Representations of Participant. Participant acknowledges that he or she has received, read and understood the Plan, the Option Agreement, the LLC Agreement, this Exercise Notice and Restricted Unit Agreement
and is familiar with their terms and provisions. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under this Agreement. 
  
 3. Rights and Obligations as a Member. Upon exercise of the Option in
compliance and in accordance with the provisions of Section 8(b) and (c) of the Plan, the Participant shall become a Common Holder and, at the discretion of the Committee, have all rights of a Common Holder with respect to said Units as provided in
the LLC Agreement. Participant, without further action on his or her part, by purchase of the Units agrees to be deemed a party to, a signatory of and bound by the LLC Agreement, and the Units shall be subject to such rights and restrictions as
contained therein. Participant shall enjoy rights as a Common Holder and shall be subject to all of the limitations, restrictions and obligations contained in the LLC Agreement as a Common Holder, until such time as Participant disposes of the Units
or the Company and/or its assignee(s) exercises the Right of First Refusal, Call Right or the Repurchase provided in this Agreement or otherwise in the LLC Agreement. Upon such exercise, Participant shall have no further rights as a holder of the
Units so purchased except the right to receive payment for the Units so purchased in accordance with the provisions of this Agreement and the LLC Agreement. 
  

 4. Participant’s Rights to Transfer Units. 
  
 (a) Limitations on Transfer. Unvested Units (or any
securities into which such Units may be converted) may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner; provided, however, that Unvested Units may, with the consent of the Committee, be (i) transferred to the
Participant’s Immediate Family, so long as such transfer is without receipt of any consideration therefore, or (ii) assigned or pledged to the Company as collateral on any loan used to acquire such Units as provided by the Plan, so long as any
Unvested Unit so transferred, assigned or pledged shall remain subject to the terms and conditions of this Agreement. Purchaser may transfer Vested Units (or any securities into which such Units may be converted), subject to the restrictions
contained in this Section 4 and the LLC Agreement; provided however no Units may be transferred (A) to a direct competitor of the Company as determined by the Board or (B) for consideration other than cash. 
  
 (b) Company’s Right of First Refusal. Before any
Vested Units (or any securities into which such Vested Units may be converted) held by Participant or any permitted transferee (each, a “Holder”) may be sold, pledged, assigned, hypothecated, transferred or otherwise disposed of
(including transfer by gift or operation of law, collectively a “Transfer” or “Transferred”), the Company or its assignee(s) shall have a right of first refusal to purchase the Vested Units on the terms and
conditions set forth in this Section (the “Right of First Refusal”). 
  
 (i) Notice of Proposed Transfer. The Holder of the Vested Units shall deliver to the Company a written notice (the
“Notice”) stating: (i) the Holder’s bona fide intention to sell or otherwise Transfer such Vested Units; (ii) the name of each proposed Participant or other transferee (“Proposed Transferee”); (iii) the number
of Vested Units to be Transferred to each Proposed Transferee; and (iv) the bona fide cash price for which the Holder proposes to Transfer the Vested Units (the “Offered Price”), and the Holder shall offer the Vested Units at the
Offered Price to the Company or its assignee(s). 
  
 (ii) Exercise of Right of First Refusal. Within thirty (30) days after receipt of the Notice, the Company and/or its assignee(s) may elect in writing to purchase all, but not less than all, of the Vested Units proposed to be
Transferred to any one or more of the Proposed Transferees. The purchase price will be determined in accordance with subsection (c) below. 
  
 (iii) Purchase Price. The purchase price (“Purchase Price”) for the Units repurchased under this Section shall be
the Offered Price. 
  
 (iv) Payment.
Payment of the Purchase Price shall be made, at the option of the Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an
assignee, to the assignee), or by any combination thereof within thirty (30) days after receipt of the Notice or in the manner and at the times set forth in the Notice. 
  
 (v) Holder’s Right to Transfer. If all of the Vested Units proposed in the Notice to be
transferred to a given Proposed Transferee are not purchased by the Company 

  

 2 

 
and/or its assignee(s) as provided in this Section, then subject to any rights of first refusal or other restrictions on transfer contained in the LLC
Agreement, the Holder may sell or otherwise Transfer such Units to that Proposed Transferee at the Offered Price or at a higher price, provided that such sale or other Transfer is consummated within one hundred twenty (120) days after the date of
the Notice and provided further that any such sale or other Transfer is effected in accordance with any applicable securities laws and the Proposed Transferee agrees in writing that the provisions of this Section and shall continue to apply to the
Vested Units in the hands of such Proposed Transferee. If the Vested Units described in the Notice are not Transferred to the Proposed Transferee within such period, a new Notice shall be given to the Company, and the Company and/or its assignees
shall again be offered the Right of First Refusal as provided herein before any Vested Units held by the Holder may be sold or otherwise Transferred. The Company’s Right of First Refusal as contained herein shall be in addition to and arise
prior to any rights of first refusal contained in the LLC Agreement. 
  
 (c) Exception for Certain Family Transfers. Anything to the contrary contained in this Section notwithstanding, the Transfer of any or all of the Units during the Participant’s lifetime or on the
Participant’s death by will or intestacy to the Participant’s Immediate Family shall be exempt from the Right of First Refusal. In such case, the transferee or other recipient shall receive and hold the Units so Transferred subject to the
provisions of this Section, Section 5, the Restricted Unit Agreement, and the LLC Agreement, as applicable, and there shall be no further Transfer of such Units except in accordance with the terms of this Section. 
  
 (d) Termination of Right of First Refusal. The Right
of First Refusal shall terminate as to all Units (and any securities into which such Units may be converted) ninety (90) days after a sale of common stock of the Company to the general public pursuant to a registration statement filed with and
declared effective by the Securities and Exchange Commission under the Securities Act of 1933, as amended (a “Public Offering”). 
  
 5. Company Call Right. 
  
 (a) If Participant ceases to be a Service Provider (as defined in the Plan) for any reason, the Company shall have the right to purchase
any or all of the Vested Units (or any securities into which such Vested Units may be converted) then owned by a Holder at a price equal to the Fair Market Value (as defined in the Plan) of the Vested Units on the date on which the Participant
ceases to be a Service Provider (the “Call Right”). 
  
 (b) The Company may exercise the Company Call Right by delivering personally or by registered mail to Holder, within ninety (90) days of the date on which Participant ceases to be a Service Provider, a notice in
writing indicating the Company’s intention to exercise the Company Call Right and setting forth a date for closing not later than thirty (30) days from the mailing of such notice. The closing shall take place at the Company’s office.

  
 (c) At its option, the Company may elect to
make payment for the Vested Units to a bank selected by the Company. The Company shall avail itself of this option by a 

  

 3 

 
notice in writing to Holder stating the name and address of the bank, date of closing, and waiving the closing at the Company’s office. 
  
 (d) If the Company does not elect to exercise the Company
Call Right conferred above by giving the requisite notice within ninety (90) days following the date on which Participant ceases to be a Service Provider, the Company Call Right shall terminate. 
  
 (e) The Company Call Right shall terminate as to all Vested
Units (or any securities into which such Vested Units may be converted) ninety (90) days after a Public Offering. 
  
 6. Repurchase. 
  
 (a) If Participant ceases to be a Service Provider (as defined in the Company’s Equity Incentive Plan) for any reason, the Company
shall purchase all of the Participant’s Unvested Units from the Holder thereof, as of the date on which Participant ceases to be a Service Provider (the “Repurchase”) at the lesser of (i) the exercise price paid by the
Participant for such Units in connection with the exercise of the Option or (i) the Fair Market Value thereof (the “Repurchase Price”). The Company shall deliver the Repurchase Price, to the Holder by check, cash or wire transfer
within ninety (90) days of the date on which Participant ceases to be a Service Provider. 
  
 (b) One hundred percent (100%) of the Unvested Units shall initially be subject to Repurchase. The Unvested Units shall be released from
Repurchase in accordance with the Vesting Schedule set forth in the Notice of Grant until all Units are released from the Repurchase obligation. 
  
 7. Spousal Consent. As a further condition to the Company’s and Participant’s obligations under this Agreement, the spouse of the
Participant, if any, shall execute and deliver to the Company the Consent of Spouse attached hereto as Exhibit C. 
  
 8. Tax Consultation. 
  
 (a) Representations. Participant understands that he or she may suffer adverse tax consequences as a result of his or her purchase
or disposition of the Units. Participant has reviewed with his or her own tax advisors the federal, state, local and foreign tax consequences of this investment and the transactions contemplated by this Agreement. Participant is relying solely on
such advisors and not on any statements or representations of the Company or any of its agents. Participant understands that he or she (and not the Company) shall be responsible for his or her own tax liability that may arise as a result of this
investment or the transactions contemplated by this Agreement. 
  
 (b) Section 83(b) Election. Participant hereby acknowledges that he or she has been informed that, with respect to the exercise of the Option for Unvested Units, that unless an election is filed by the
Participant with the Internal Revenue Service and, if necessary, the proper state taxing authorities, within thirty (30) days of the purchase of the Units, electing pursuant to Section 83(b) of the Code (and similar state tax provisions if
applicable) to be taxed currently on any difference between the purchase price of the Units and their Fair Market Value 

  

 4 

 
on the date of purchase, there will be a recognition of taxable income to the Participant, measured by the excess, if any, of the Fair Market Value of the
Units, at the time the Repurchase lapses over the purchase price for the Units. Participant represents that Participant has consulted any tax consultant(s) Participant deems advisable in connection with the purchase of the Units or the filing of the
election under Section 83(b) and similar tax provisions. 
  
 PARTICIPANT ACKNOWLEDGES THAT IT IS HIS OR HER SOLE RESPONSIBILITY AND NOT THE COMPANY’S TO FILE TIMELY THE ELECTION UNDER SECTION 83(b), EVEN IF PARTICIPANT REQUESTS THE COMPANY OR ITS REPRESENTATIVE TO MAKE THIS FILING ON HIS OR HER
BEHALF 
  
 9. Refusal to Transfer. The Company shall not be
required (i) to transfer on its books any Units that have been sold or otherwise transferred in violation of any of the provisions of the this Agreement or the LLC Agreement or (ii) to treat as owner of such Units or to accord the right to vote or
pay dividends to any Participant or other transferee to whom such Units shall have been so transferred. 
  
 10. No Right to Employment. 
  
 PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE UNVESTED UNITS HEREIN GRANTED CONTINUE TO VEST ONLY FOR PERIODS DETERMINED WITH REFERENCE TO THE PERIOD OF
CONTINUED CONSULTANCY OR EMPLOYMENT AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED OR ACQUIRING UNITS HEREUNDER). PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS AGREEMENT, NOR IN THE COMPANY’S
EQUITY INCENTIVE PLAN WHICH IS INCORPORATED HEREIN BY REFERENCE, SHALL CONFER UPON PARTICIPANT ANY RIGHT WITH RESPECT TO CONTINUATION OF EMPLOYMENT OR CONSULTANCY BY THE COMPANY, NOR SHALL IT INTERFERE IN ANY WAY WITH PARTICIPANT’S RIGHT OR THE
COMPANY’S RIGHT TO TERMINATE PARTICIPANT’S EMPLOYMENT OR CONSULTANCY AT ANY TIME, WITH OR WITHOUT CAUSE OR NOTICE. 
  
 11. Successors and Assigns. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall
inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth, this Agreement shall be binding upon Participant and his or her heirs, executors, successors, and assigns. 
  
 12. Interpretation. Any dispute regarding the interpretation of this
Agreement shall be submitted by Participant or by the Company forthwith to the Company’s Board of Managers or committee thereof that is responsible for the administration of the Plan (the “Committee”), which shall review such
dispute at its next regular meeting. The resolution of such a dispute by the Committee shall be final and binding on the Company and on any Holder. 
  

 5 

 13. Governing Law; Severability. This Agreement shall be governed by and construed in accordance
with the laws of the State of Delaware excluding that body of law pertaining to conflicts of law. Should any provision of this Agreement be determined by a court of law to be illegal or unenforceable, the other provisions shall nevertheless remain
effective and shall remain enforceable. 
  
 14. Notices.
Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery or upon deposit in the United States mail by certified mail, with postage and fees prepaid, addressed to the other
party at its address as shown below beneath its signature, or to such other address as such party may designate in writing from time to time to the other party. Participant further agrees to notify the Company upon any change in the residence
address indicated below. 
  
 15. Further Instruments. The
parties agree to execute such further instruments and to take such further action as may be reasonably necessary to carry out the purposes and intent of this Agreement. 
  
 16. Delivery of Payment. Participant herewith delivers to the Company the full Exercise Price for the Shares, as well
as any applicable withholding tax. 
  
 17. Entire
Agreement. The Plan, Option Agreement and LLC Agreement are incorporated herein by reference. This Agreement, the Plan, the Option Agreement, and the Investment Representation Statement, if applicable, constitute the entire agreement of the
parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. 
  

									
	 Submitted by:
	 	 	 	 Accepted by:

			
	 PARTICIPANT:
	 	 	 	RELIANT PHARMACEUTICALS, LLC
				
	 	 	 	 	By:	 	 
				
	 	 	 	 	Its:	 	 
				
	 Address:
	 	 	 	 	 	 
				
	 	 	 	 	 	 	 
				
	 	 	 	 	 	 	 
				
	 	 	 	 	 	 	 

  

 6 

  
 EXHIBIT B

  
 INVESTMENT REPRESENTATION STATEMENT 

 

					
	 PARTICIPANT
	 	 :
	  	 
			
	 COMPANY
	 	 :
	  	 RELIANT PHARMACEUTICALS, LLC

			
	 SECURITY
	 	 :
	  	 CLASS ONE COMMON UNITS

			
	 AMOUNT
	 	 :
	  	 
			
	 DATE
	 	 :
	  	 

  
 In connection with the
purchase of the above-listed Securities, the undersigned Participant represents to the Company the following: 
  
 (a) Participant is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach
an informed and knowledgeable decision to acquire the Securities. Participant is acquiring these Securities for investment for Participant’s own account only and not with a view to, or for resale in connection with, any
“distribution” thereof within the meaning of the Securities Act of 1933, as amended (the “Securities Act”). 
  
 (b) Participant acknowledges and understands that the Securities constitute “restricted securities” under the Securities Act and have not
been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Participant’s investment intent as expressed herein. In this connection,
Participant understands that, in the view of the Securities and Exchange Commission, the statutory basis for such exemption may be unavailable if Participant’s representation was predicated solely upon a present intention to hold these
Securities for the minimum capital gains period specified under tax statutes, for a deferred sale, for or until an increase or decrease in the market price of the Securities, or for a period of one year or any other fixed period in the future.
Participant further understands that the Securities must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available. Participant further acknowledges and understands that
the Company is under no obligation to register the Securities. 
  
 (c) Participant is familiar with the provisions of Rule 701 and Rule 144, each promulgated under the Securities Act, which, in substance, permit limited public resale of “restricted securities” acquired, directly or
indirectly from the issuer thereof, in a non-public offering (or held by any affiliate of the issuer), subject to the satisfaction of certain conditions. Rule 701 provides that if the issuer qualifies under Rule 701 at the time of the grant of the
Option to the Participant, the exercise will be exempt from registration under the Securities Act. In the event the Company becomes subject to the reporting requirements of Section 13 or 15(d) 

  

 
of the Securities Exchange Act of 1934, ninety (90) days thereafter (or such longer period as any market stand-off agreement may require) the Securities
exempt under Rule 701 may be resold, subject to the satisfaction of certain of the conditions specified by Rule 144, including: (1) the resale being made through a broker in an unsolicited “broker’s transaction” or in
transactions directly with a market maker (as said term is defined under the Securities Exchange Act of 1934); and, in the case of an affiliate, (2) the availability of certain public information about the Company, (3) the amount of Securities being
sold during any three (3) month period not exceeding the limitations specified in Rule 144(e), and (4) the timely filing of a Form 144, if applicable. 
  
 In the event that the Company does not qualify under Rule 701 at the time of grant of the Option, then the Securities may be resold in certain limited
circumstances subject to the provisions of Rule 144, which requires the resale to occur not less than one year after the later of the date the Securities were sold by the Company or the date the Securities were sold by an affiliate of the Company,
within the meaning of Rule 144; and, in the case of acquisition of the Securities by an affiliate, or by a non-affiliate who subsequently holds the Securities less than two (2) years, the satisfaction of the conditions set forth in sections (1),
(2), (3) and (4) of the paragraph immediately above. 
  
 (d)
Participant further understands that in the event all of the applicable requirements of Rule 701 or 144 are not satisfied, registration under the Securities Act, compliance with Regulation A, or some other registration exemption will be required;
and that, notwithstanding the fact that Rules 144 and 701 are not exclusive, the Staff of the Securities and Exchange Commission has expressed its opinion that persons proposing to sell private placement securities other than in a registered
offering and otherwise than pursuant to Rules 144 or 701 will have a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective brokers who
participate in such transactions do so at their own risk. Participant understands that no assurances can be given that any such other registration exemption will be available in such event. 
  

	
	 Signature of Participant:

	
	 

  
 Date:
                                ,
         
  

 2 

  
 EXHIBIT C

  
 CONSENT OF SPOUSE 
  
 I,
                                , spouse of
                         have read and approve the foregoing Agreement. In consideration of granting of the right to my
spouse to purchase Class One Common Units of Reliant Pharmaceuticals, LLC as set forth in the Agreement, I hereby appoint my spouse as my attorney-in-fact in respect to the exercise of any rights under the Agreement and agree to be bound by the
provisions of the Agreement insofar as I may have any rights in said Agreement or any shares issued pursuant thereto under the community property laws or similar laws relating to marital property in effect in the state of our residence as of the
date of the signing of the foregoing Agreement. 
  
 Dated:
                                ,

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}]]